# OnCo record nct07221500 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07221500/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07221500", "NCT07221500" ;
  schema:name "A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)"@en ;
  schema:alternateName "DAYBreak CLL-201"@en ;
  schema:description "A phase 2 trial of Bexobrutideg in chronic lymphocytic leukaemia, run by Nurix Therapeutics, Inc., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07221500/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07221500> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2025-10-15" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/cll-relapsed/> ;
  onco:drugs <https://onco.cc/drugs/bexobrutideg/> ;
  onco:companies <https://onco.cc/companies/nurix/> .